<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301884</url>
  </required_header>
  <id_info>
    <org_study_id>GBIRB2013-35</org_study_id>
    <nct_id>NCT02301884</nct_id>
  </id_info>
  <brief_title>Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis</brief_title>
  <acronym>pILIT</acronym>
  <official_title>Open-labeled Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gachon University Gil Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thermo Fisher Scientific</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed open-labeled pilot study which evaluates the efficacy and safety
      of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including
      Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are
      sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After informed consent, causal allergen was injected into inguinal lymph node through
      guidance by ultrasonography three times with 4-week interval. Initial dose of allergen was
      1,000-fold diluted solution from maximal concentration of allergen extract for subcutaneous
      immunotherapy (30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and 1:1/10 weight/volume for dog
      hair/dander, HollisterStier, New Orleans, USA) in volume of 0.1ml. After the first dose,
      allergen concentration was escalated 3-fold at second dose, and 10-fold at third dose if
      there was no or mild local or systemic hypersensitivity reaction. The allergen concentration
      did not change at second or third dose if there was moderate local or systemic reaction. The
      allergen concentration was decreased by 10 or 100-fold from previous concentration if there
      was severe local or systemic reaction.

      The investigators evaluated parameters regarding allergic rhinitis within a week before the
      first injection and 4 months after the first injection. These parameters included
      Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and Sino-Nasal Outcome Test
      (SNOT-20), and Visual analogue scale (VAS) of symptoms including rhinorrhea, sneezing, nasal
      obstruction, postnasal drip, eye/nose/ear/palate itching, dyspnea, wheezing, chest discomfort
      as well as urticaria, angioedema, and itching on exposed skin during exposure to causal
      allergen in daily life. Skin prick test, intradermal test, blood sampling for serum
      allergen-specific IgE, exhaled nitric oxide, and nasal lavage for Th1, Th2, and Treg
      cytokines were also included. Adverse events were recorded and graded according to Muller's
      classification and Ring and Messmer's classification.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RQLQ</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Rhinoconjunctivitis Quality of Life Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SNOT-20</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Sino-Nasal Outcome Test-20</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin reactivity</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Allergen/histamine ratio of mean wheal diameter in skin prick test, and allergen/saline ratio of mean wheal diameter in intradermal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum total and allergen-specific IgE and IgG4 level</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Serum total and allergen-specific IgE and IgG4 level using UNICAP, Thermofisher Scientific, Sweden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal reactivity</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Symptom score and volume 2-6 cm in acoustic rhinometry during nasal provocation test with D. farinae and/or D. pteronyssinus in allergic rhinitis patients sensitized to house dust mite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines in nasal lavage fluid</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Cytokines of Th1, Th2, and Treg in nasal lavage fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exhaled NO</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Exhaled nitric oxide measuring NIOX MINO, Thermofisher Scientific, Sweden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory and dermatologic symptoms provoked by allergen exposure in daily life</measure>
    <time_frame>Baseline and 4 months after the first injection</time_frame>
    <description>Visual analogue scale of respiratory and dermatologic symptoms provoked by allergen exposure in daily life (ranged from 0 to 100)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allergen extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Causal allergen such as D. farinae (30 AU/ml), D. pteronyssinus (30 AU/ml), cat hair (10 AU/ml), dog hair/dander (1:1/10 w/v), or combination of those.
Allergen extract, HollisterStier, New Orleans, USA. Intralymphatic injection in volume of 0.1 ml, three times with 4-week interval. Concentration was increased, decreased, or unchanged at 2nd or 3rd injection according to local or systemic reaction after previous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergen extract</intervention_name>
    <description>Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those</description>
    <arm_group_label>Allergen extract</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allergic rhinitis to house dust mite (Df, Dp), cat or dog

          -  More than 3mm reaction at skin prick test for Df, Dp, cat or dog or more than class 3
             at serum specific IgE level (UNICAP or MAST)

        Exclusion Criteria:

          -  Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA)
             guideline

          -  FEV1 less than 50% of predicted value if there is comorbid asthma

          -  Subject rejects the enrollment into study

          -  Low compliance

          -  Pregnancy or lactation

          -  Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious
             diseases

          -  Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic
             antidepressant, immunosuppressant including systemic glucocorticosteroid (20mg or more
             dose of prednisolone or equivalent dose of other steroid) within last 2 weeks

          -  Prior history of allergen-specific immunotherapy

          -  Allergic rhinitis caused by other perennial or seasonal allergen

          -  Vulnerable volunteer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Min Lee, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gachon University Gil Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Zaleska A, Eiwegger T, Soyer O, van de Veen W, Rhyner C, Soyka MB, Bekpen C, Demiröz D, Treis A, Söllner S, Palomares O, Kwok WW, Rose H, Senti G, Kündig TM, Ozoren N, Jutel M, Akdis CA, Crameri R, Akdis M. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy. 2014 Sep;69(9):1162-70. doi: 10.1111/all.12461. Epub 2014 Jul 12. Erratum in: Allergy. 2016 Jan;71(1):129.</citation>
    <PMID>24934402</PMID>
  </reference>
  <results_reference>
    <citation>Kündig TM, Johansen P, Bachmann MF, Cardell LO, Senti G. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014 Mar;133(3):930-1. doi: 10.1016/j.jaci.2013.11.036. Epub 2014 Jan 15.</citation>
    <PMID>24439076</PMID>
  </results_reference>
  <results_reference>
    <citation>Witten M, Malling HJ, Blom L, Poulsen BC, Poulsen LK. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013 Nov;132(5):1248-1252.e5. doi: 10.1016/j.jaci.2013.07.033. Epub 2013 Sep 13.</citation>
    <PMID>24035151</PMID>
  </results_reference>
  <results_reference>
    <citation>Senti G, Crameri R, Kuster D, Johansen P, Martinez-Gomez JM, Graf N, Steiner M, Hothorn LA, Grönlund H, Tivig C, Zaleska A, Soyer O, van Hage M, Akdis CA, Akdis M, Rose H, Kündig TM. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012 May;129(5):1290-6. doi: 10.1016/j.jaci.2012.02.026. Epub 2012 Mar 30.</citation>
    <PMID>22464647</PMID>
  </results_reference>
  <results_reference>
    <citation>Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr Top Microbiol Immunol. 2011;352:71-84. doi: 10.1007/82_2011_133. Review.</citation>
    <PMID>21725898</PMID>
  </results_reference>
  <results_reference>
    <citation>Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009 Dec;9(6):537-43. doi: 10.1097/ACI.0b013e3283310ff7. Review.</citation>
    <PMID>19680119</PMID>
  </results_reference>
  <results_reference>
    <citation>Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, Johansen P, Kündig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17908-12. doi: 10.1073/pnas.0803725105. Epub 2008 Nov 10.</citation>
    <PMID>19001265</PMID>
  </results_reference>
  <results_reference>
    <citation>Hylander T, Latif L, Petersson-Westin U, Cardell LO. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013 Feb;131(2):412-20. doi: 10.1016/j.jaci.2012.10.056.</citation>
    <PMID>23374268</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>March 10, 2015</last_update_submitted>
  <last_update_submitted_qc>March 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Medical Center</investigator_affiliation>
    <investigator_full_name>Sang Min Lee</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

